

Marc Carrier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1579203/publications.pdf>

Version: 2024-02-01

248
papers

14,827
citations

53939

47
h-index

23841

115
g-index

253
all docs

253
docs citations

253
times ranked

15622
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
2	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018, 378, 615-624.	13.9	1,237
3	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	13.9	778
4	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	13.9	712
5	Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 711-719.	13.9	614
6	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. <i>Chest</i> , 2020, 158, 1143-1163.	0.4	531
7	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. <i>Blood Advances</i> , 2021, 5, 927-974.	2.5	431
8	Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2010, 152, 578.	2.0	401
9	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. <i>New England Journal of Medicine</i> , 2018, 378, 699-707.	13.9	294
10	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019, 179, 1469.	2.6	283
11	Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. <i>Gastroenterology</i> , 2014, 146, 835-848.e6.	0.6	277
12	Systematic Review: The Trousseau Syndrome Revisited: Should We Screen Extensively for Cancer in Patients with Venous Thromboembolism?. <i>Annals of Internal Medicine</i> , 2008, 149, 323.	2.0	261
13	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. <i>BMJ, The</i> , 2021, 375, n2400.	3.0	250
14	Screening for Occult Cancer in Unprovoked Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2015, 373, 697-704.	13.9	239
15	Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 173, 158-163.	0.8	228
16	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
17	Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism. <i>Circulation</i> , 2012, 126, 448-454.	1.6	179
18	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 366, l4363.	2.4	177

#	ARTICLE	IF	CITATIONS
19	Guidance for the prevention and treatment of cancer-associated venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 81-91.	1.0	169
20	Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. <i>BMJ</i> , The, 2013, 347, f5133-f5133.	3.0	158
21	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 842-851.	1.8	157
22	Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. <i>Thrombosis Research</i> , 2014, 134, 1214-1219.	0.8	154
23	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	1.8	154
24	Perioperative Management of Dabigatran. <i>Circulation</i> , 2015, 132, 167-173.	1.6	133
25	Lack of Evidence to Support Thromboprophylaxis in Hospitalized Medical Patients with Cancer. <i>American Journal of Medicine</i> , 2014, 127, 82-86.e1.	0.6	132
26	Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1122.	3.8	126
27	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017, 151, 89-95.	0.8	109
28	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1772-1778.	1.9	107
29	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Blood</i> , 2020, 136, 1433-1441.	0.6	106
30	Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2017, 167, 410.	2.0	96
31	Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. <i>BMJ Open</i> , 2014, 4, e004301-e004301.	0.8	93
32	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2126-2137.	1.9	84
33	Effect of Antiplatelet Therapy on Survival and Organ Supportâ€œFree Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1247.	3.8	83
34	Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. <i>Thrombosis Research</i> , 2015, 136, 727-731.	0.8	78
35	The impact of oral anticoagulation on time to surgery in patients hospitalized with hip fracture. <i>Thrombosis Research</i> , 2015, 136, 962-965.	0.8	77
36	Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>New England Journal of Medicine</i> , 2021, 385, 857-859.	13.9	70

#	ARTICLE	IF	CITATIONS
37	A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. <i>Blood</i> , 2016, 127, 1650-1655.	0.6	67
38	Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2014, 133, 682-687.	0.8	66
39	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2415-2424.	1.8	62
40	Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1247-1252.	1.9	60
41	Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. <i>Thrombosis Research</i> , 2008, 123, 177-183.	0.8	58
42	Thromboprophylaxis in Patients With COVID-19. <i>Chest</i> , 2022, 162, 213-225.	0.4	58
43	Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. <i>Clinical Trials</i> , 2020, 17, 491-500.	0.7	56
44	Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults. <i>Thrombosis Research</i> , 2017, 157, 64-71.	0.8	53
45	Incidental venous thromboembolism: is anticoagulation indicated?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 121-127.	0.9	52
46	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. <i>Chest</i> , 2017, 151, 564-571.	0.4	51
47	Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. <i>Thrombosis Research</i> , 2014, 134, 93-95.	0.8	50
48	Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. <i>Thrombosis Research</i> , 2015, 135, 298-302.	0.8	49
49	Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. <i>Blood</i> , 2016, 127, 2035-2037.	0.6	47
50	Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 664-669.	1.0	47
51	How I treat cancer-associated venous thromboembolism. <i>Blood</i> , 2019, 133, 291-298.	0.6	45
52	Incidence and risk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients. <i>Thrombosis Research</i> , 2014, 133, 30-33.	0.8	44
53	Comprehensive mitigation framework for concurrent application of multiple clinical practice guidelines. <i>Journal of Biomedical Informatics</i> , 2017, 66, 52-71.	2.5	44
54	Symptomatic subsegmental pulmonary embolism: to treat or not to treat?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 237-241.	0.9	44

#	ARTICLE	IF	CITATIONS
55	Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1866-1874.	1.9	42
56	VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies. <i>Thrombosis and Haemostasis</i> , 2009, 101, 886-92.	1.8	42
57	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2141-2151.	1.9	41
58	Randomized trials of therapeutic heparin for COVID-19: A meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12638.	1.0	39
59	Cancer, atrial fibrillation, and stroke. <i>Thrombosis Research</i> , 2017, 155, 101-105.	0.8	36
60	Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. <i>Thrombosis Research</i> , 2018, 163, 41-46.	0.8	36
61	Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1761-1768.	0.9	35
62	The prevalence of antibodies to the platelet factor 4-heparin complex and association with access thrombosis in patients on chronic hemodialysis. <i>Thrombosis Research</i> , 2007, 120, 215-220.	0.8	33
63	Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. <i>JAMA Internal Medicine</i> , 2020, 180, 1052.	2.6	33
64	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. <i>Annals of Internal Medicine</i> , 2022, 175, 29-35.	2.0	33
65	Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. <i>Blood</i> , 2017, 129, 934-939.	0.6	32
66	Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 282-290.	1.0	32
67	Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 457.e1-457.e8.	0.8	31
68	Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 479-489.	1.8	31
69	A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1493-1501.	1.9	31
70	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020, 55, 1901697.	3.1	31
71	A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making. <i>PLoS ONE</i> , 2018, 13, e0207410.	1.1	29
72	Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. <i>Heart</i> , 2019, 105, 545-552.	1.2	29

#	ARTICLE	IF	CITATIONS
73	Management of venous thromboembolism in patients with glioma. <i>Thrombosis Research</i> , 2017, 156, 105-108.	0.8	28
74	Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. <i>Thrombosis Research</i> , 2018, 164, S124-S129.	0.8	28
75	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. <i>Thrombosis Research</i> , 2018, 162, 104-109.	0.8	27
76	Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. <i>American Journal of Surgery</i> , 2019, 218, 537-550.	0.9	27
77	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	1.9	27
78	Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 212-220.	1.9	27
79	VTE Prophylaxis in Critically Ill Adults. <i>Chest</i> , 2022, 161, 418-428.	0.4	27
80	Outcomes in a nurse-led peripherally inserted central catheter program: a retrospective cohort study. <i>CMAJ Open</i> , 2017, 5, E535-E539.	1.1	26
81	The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 278-284.	1.9	26
82	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. <i>Current Oncology</i> , 2021, 28, 5434-5451.	0.9	26
83	Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2017, 151, 67-71.	0.8	25
84	Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. <i>Thrombosis Research</i> , 2017, 152, 52-60.	0.8	25
85	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 646-656.	1.8	25
86	Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS-PTS study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 857-864.	1.9	24
87	Prophylactic and therapeutic anticoagulation for thrombosis—major issues in oncology. <i>Nature Clinical Practice Oncology</i> , 2009, 6, 74-84.	4.3	23
88	Controversies in the management of cancer-associated thrombosis. <i>Expert Review of Hematology</i> , 2017, 10, 15-22.	1.0	23
89	Ideating Mobile Health Behavioral Support for Compliance to Therapy for Patients with Chronic Disease: A Case Study of Atrial Fibrillation Management. <i>Journal of Medical Systems</i> , 2018, 42, 234.	2.2	23
90	Effect of oral anticoagulant use on surgical delay and mortality in hip fracture. <i>Bone and Joint Journal</i> , 2021, 103-B, 222-233.	1.9	23

#	ARTICLE	IF	CITATIONS
91	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapiesâ€”TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2068-2081.	1.9	23
92	Efficacy and Safety of Low Molecular Weight Heparin Versus Unfractionated Heparin for Prevention of Venous Thromboembolism in Trauma Patients. <i>Annals of Surgery</i> , 2022, 275, 19-28.	2.1	23
93	Costâ€effectiveness analysis of lowâ€dose direct oral anticoagulant (DOAC) for the prevention of cancerâ€associated thrombosis in the United States. <i>Cancer</i> , 2020, 126, 1736-1748.	2.0	23
94	The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 760-762.	0.5	22
95	Periprocedural interruption of anticoagulation in patients with cancerâ€associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1171-1178.	1.9	22
96	Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3174-3183.	1.9	22
97	Thrombotic Complications Associated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 4606.	1.7	22
98	Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and metaâ€analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2468-2479.	1.9	21
99	Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2018, 171, 92-96.	0.8	20
100	Diagnostic accuracy of three ultrasonography strategies for deep vein thrombosis of the lower extremity: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0228788.	1.1	20
101	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Haematologica</i> , 2020, 105, 1436-1442.	1.7	19
102	Hyperacute multi-organ thromboembolic storm in COVID-19: a case report. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 25-28.	1.0	19
103	Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID) Tj ETQq1 1 0,784314 rgBT /Ov <i>Trials</i> , 2021, 22, 202.	0.7	19
104	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. <i>Blood Advances</i> , 2022, 6, 3569-3578.	2.5	19
105	Excluding pulmonary embolism at the bedside with low pre-test probability and D-dimer: Safety and clinical utility of 4 methods to assign pre-test probability. <i>Thrombosis Research</i> , 2006, 117, 469-474.	0.8	18
106	The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 65-74.	1.0	18
107	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021, 05, e376-e386.	0.7	18
108	Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants. <i>Thrombosis Research</i> , 2014, 133, S167-S171.	0.8	17

#	ARTICLE	IF	CITATIONS
109	Using Semantic Components to Represent Dynamics of an Interdisciplinary Healthcare Team in a Multi-Agent Decision Support System. <i>Journal of Medical Systems</i> , 2016, 40, 42.	2.2	17
110	How I treat obese patients with oral anticoagulants. <i>Blood</i> , 2020, 135, 904-911.	0.6	17
111	The efficacy and safety of anticoagulation in cerebral vein thrombosis: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2018, 169, 135-139.	0.8	16
112	Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 495-504.	1.0	16
113	Prevention of venous thromboembolism in ambulatory patients with cancer. <i>ESMO Open</i> , 2020, 5, e000948.	2.0	16
114	Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1270-1278.	1.8	15
115	The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 832-846.	1.8	15
116	Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature. <i>Thrombosis Research</i> , 2021, 204, 114-122.	0.8	15
117	Venous thromboembolism and occult cancer: impact on clinical practice. <i>Thrombosis Research</i> , 2016, 140, S8-S11.	0.8	14
118	Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. <i>BMJ Open</i> , 2017, 7, e015562.	0.8	14
119	Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 489-501.	1.9	14
120	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3031-3043.	1.9	14
121	Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2016, 138, 1-6.	0.8	13
122	Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next?. <i>Thrombosis Research</i> , 2019, 180, 105-109.	0.8	13
123	Clinical Surveillance vs. Anticoagulation For low-risk patients with isolated Subsegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE). <i>BMJ Open</i> , 2020, 10, e040151.	0.8	13
124	Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1526-1532.	1.9	12
125	Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2618-2628.	1.9	12
126	Thromboembolic disease in palliative and end-of-life care: A narrative review. <i>Thrombosis Research</i> , 2019, 175, 84-89.	0.8	11

#	ARTICLE	IF	CITATIONS
127	Anticoagulation for Subsegmental Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2019, 381, 1171-1174.	13.9	11
128	Ventilation/perfusion SPECT for the diagnosis of pulmonary embolism: A systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2910-2920.	1.9	11
129	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021, 202, 151-154.	0.8	11
130	SPECT V/Q for the diagnosis of pulmonary embolism: protocol for a systematic review and meta-analysis of diagnostic accuracy and clinical outcome. <i>BMJ Open</i> , 2018, 8, e022024.	0.8	10
131	Venous thromboembolism and transfusion after major abdominopelvic surgery. <i>Surgery</i> , 2019, 166, 1084-1091.	1.0	10
132	Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2622-2628.	1.9	10
133	Screening for Occult Cancer in Patients with Venous Thromboembolism. <i>Journal of Clinical Medicine</i> , 2020, 9, 2389.	1.0	10
134	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. <i>Thrombosis Research</i> , 2020, 191, S31-S36.	0.8	10
135	Effect of oral anticoagulants on hemostatic and thromboembolic complications in hip fracture: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2566-2581.	1.9	10
136	MitPlan: A planning approach to mitigating concurrently applied clinical practice guidelines. <i>Artificial Intelligence in Medicine</i> , 2021, 112, 102002.	3.8	10
137	Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2022, 122, 830-841.	1.8	10
138	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3008-3017.	1.9	10
139	Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial. <i>Thrombosis Research</i> , 2022, 216, 8-10.	0.8	10
140	Management of pregnancy associated venous-thromboembolism: a survey of practices. <i>Thrombosis Journal</i> , 2014, 12, 12.	0.9	9
141	Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2018, 164, S7-S11.	0.8	9
142	Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1886-1887.	1.8	9
143	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. <i>Oncologist</i> , 2020, 25, 1075-1083.	1.9	9
144	Surgery and the Subtype of Inflammatory Bowel Disease Impact the Risk of Venous Thromboembolism After Hospital Discharge. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2471-2479.	1.1	9

#	ARTICLE	IF	CITATIONS
145	Incidence and Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Agents. <i>Blood</i> , 2016, 128, 2624-2624.	0.6	9
146	Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. <i>Cmaj</i> , 2021, 193, E1551-E1560.	0.9	9
147	Should we screen patients with unprovoked venous thromboembolism for occult cancers? A pilot study. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 709-710.	0.5	8
148	Occult cancer detection in venous thromboembolism: the past, the present, and the future. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 9-13.	1.0	8
149	A new prognostic strategy for adult patients with acute pulmonary embolism eligible for outpatient therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 326-332.	1.0	8
150	Patient-Centered Outcomes in the Management of Anemia: A Scoping Review. <i>Transfusion Medicine Reviews</i> , 2019, 33, 7-11.	0.9	8
151	Implanted vascular access device related deep vein thrombosis in oncology patients: A prospective cohort study. <i>Thrombosis Research</i> , 2019, 177, 117-121.	0.8	8
152	Patient-Centred Outcomes in Anaemia and Renal Disease: A Systematic Review. <i>Kidney Diseases (Basel)</i> , 2020, 12, 100-108.	1.2	8
153	A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models. <i>Thrombosis Research</i> , 2020, 195, 103-113.	0.8	8
154	A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. <i>Pilot and Feasibility Studies</i> , 2020, 6, 52.	0.5	8
155	Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. <i>Thrombosis Research</i> , 2020, 194, 26-32.	0.8	8
156	Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes. <i>Thrombosis Research</i> , 2020, 195, 21-28.	0.8	8
157	Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021, 197, 13-15.	0.8	8
158	Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12517.	1.0	8
159	Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, 1137-1146.	2.0	8
160	Heparin - Messiah or Verschlimmbesserung?. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2373-2382.	1.9	8
161	Timing of Perioperative Pharmacologic Thromboprophylaxis Initiation and its Effect on Venous Thromboembolism and Bleeding Outcomes: A Systematic Review and Meta-Analysis. <i>Journal of the American College of Surgeons</i> , 2021, 233, 619-631.	0.2	8
162	Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 977-985.	1.5	8

#	ARTICLE	IF	CITATIONS
163	Growth differentiation factor-15 for prediction of bleeding in cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 20, 138.	1.9	8
164	Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults. <i>CJC Open</i> , 2022, 4, 315-323.	0.7	8
165	POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes. <i>Chest</i> , 2022, 161, 1446-1448.	0.4	8
166	Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. <i>American Journal of Hematology</i> , 2022, 97, 1044-1054.	2.0	8
167	Thromboprophylaxis in Cancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 395-400.	1.5	7
168	Determining the safety of enoxaparin prophylaxis in critically ill patients with severe renal insufficiency – The PACER pilot study. <i>Thrombosis Research</i> , 2016, 144, 69-71.	0.8	7
169	Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants. <i>Cancer Treatment and Research</i> , 2019, 179, 103-115.	0.2	7
170	An ontology-driven framework to support the dynamic formation of an interdisciplinary healthcare team. <i>International Journal of Medical Informatics</i> , 2020, 136, 104075.	1.6	7
171	Treatment of portal vein thrombosis: an updated narrative review. <i>Minerva Medica</i> , 2022, 112, .	0.3	7
172	Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism. <i>Blood Advances</i> , 2022, 6, 4605-4616.	2.5	7
173	Should we screen extensively for cancer after unprovoked venous thrombosis?. <i>BMJ: British Medical Journal</i> , 2017, 356, j1081.	2.4	6
174	A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients post major abdominal surgery. <i>Thrombosis Journal</i> , 2017, 15, 2.	0.9	6
175	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, 016950.	0.8	6
176	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. <i>Thrombosis Research</i> , 2018, 163, 19-21.	0.8	6
177	Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 131-140.	1.0	6
178	From cellular function to global impact: the vascular perspective on COVID-19. <i>Canadian Journal of Surgery</i> , 2021, 64, E289-E297.	0.5	6
179	A Health eLearning Ontology and Procedural Reasoning Approach for Developing Personalized Courses to Teach Patients about Their Medical Condition and Treatment. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7355.	1.2	6
180	Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant. <i>Blood</i> , 2018, 132, LBA-5-LBA-5.	0.6	6

#	ARTICLE	IF	CITATIONS
181	A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study. <i>Blood</i> , 2017, 130, LBA-6-LBA-6.	0.6	6
182	Cancer Screening After Unprovoked Venous Thromboembolism. <i>JAMA Internal Medicine</i> , 2016, 176, 739.	2.6	5
183	Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 313-320.	1.0	5
184	Challenging anticoagulation cases: A case of pulmonary embolism shortly after spontaneous brain bleeding. <i>Thrombosis Research</i> , 2021, 200, 41-47.	0.8	5
185	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2021, 208, 58-65.	0.8	5
186	How to manage patients with symptomatic subsegmental pulmonary embolism?. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 310-316.	0.3	5
187	Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: protocol for a systematic review and meta-analysis of individual participant data. <i>BMJ Open</i> , 2018, 8, e023939.	0.8	4
188	What's new in the prevention and treatment of cancer-associated thrombosis?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 158-166.	0.9	4
189	Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?. <i>Blood</i> , 2020, 136, 669-673.	0.6	4
190	Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 720-724.	1.0	4
191	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. <i>Blood</i> , 2018, 132, 2527-2527.	0.6	4
192	A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis. <i>Blood</i> , 2015, 126, 893-893.	0.6	4
193	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021, 208, 79-82.	0.8	4
194	Growth Differentiation Factor-15, High-Sensitivity Cardiac Troponin T, and N-Terminal pro-B-type Natriuretic Peptide for Predicting Risk of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1169-1176.	1.8	4
195	Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 381.e1-381.e7.	0.8	4
196	Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors. <i>JAMA Network Open</i> , 2022, 5, e2219128.	2.8	4
197	Should we regionalize the management of pulmonary embolism?. <i>Cmaj</i> , 2008, 178, 58-60.	0.9	3
198	Defining time in therapeutic range for busy clinicians: Frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin. <i>Thrombosis Research</i> , 2014, 134, 584-586.	0.8	3

#	ARTICLE	IF	CITATIONS
199	The importance of post thrombotic syndrome as an outcome after deep venous thrombosis: A survey of Canadian thrombosis clinicians. <i>Thrombosis Research</i> , 2017, 159, 13-15.	0.8	3
200	Occult cancer detection in patients with hemostatic disorder and venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 242-245.	0.8	3
201	Debate: Thromboprophylaxis should be considered in all patients with cancer – Yes. <i>Thrombosis Research</i> , 2020, 191, 142-144.	0.8	3
202	Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. <i>Haematologica</i> , 2020, 105, e307-e309.	1.7	3
203	Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 214-223.	1.0	3
204	Thromboprophylaxis practice patterns and beliefs among physicians treating patients with abdominopelvic cancers at a Canadian centre. <i>Canadian Journal of Surgery</i> , 2020, 63, E562-E568.	0.5	3
205	Prognostic Factors Associated With Development of Venous Thromboembolism in Critically Ill Patients – A Systematic Review and Meta-Analysis. <i>Critical Care Medicine</i> , 2022, 50, e370-e381.	0.4	3
206	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2021, 0, .	1.8	3
207	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial. <i>Thrombosis Research</i> , 2022, 211, 85-87.	0.8	3
208	Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH-ASCC subcommittee on hemostasis and malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1920-1927.	1.9	3
209	Catheter-related thrombosis: Unresolved issues. <i>Thrombosis Research</i> , 2015, 136, 1055-1056.	0.8	2
210	A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness. <i>Thrombosis Journal</i> , 2015, 13, 10.	0.9	2
211	Guiding curriculum development of a national research training program in thrombosis medicine: A needs assessment involving faculty and trainees. <i>Thrombosis Research</i> , 2018, 162, 79-86.	0.8	2
212	Illustrated State of the Art Capsules of the ISTH 2021 Congress. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12532.	1.0	2
213	The Risk of Venous Thromboembolism in Pregnant Women with Essential Thrombocythemia: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2016, 128, 2595-2595.	0.6	2
214	Factors Associated With Inferior Vena Cava Filter Placement and Retrieval for Patients With Cancer-Associated Thrombosis. <i>American Journal of Medicine</i> , 2022, 135, 478-487.e5.	0.6	2
215	Anticoagulation in thrombocytopenic patients – time to rethink?. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	1.9	2
216	The efficacy and safety of anticoagulation in cerebral vein thrombosis: A Systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 180, 28.	0.8	1

#	ARTICLE	IF	CITATIONS
217	Just the facts: Management of life-threatening bleeding with oral anticoagulant use in the emergency department. <i>Canadian Journal of Emergency Medicine</i> , 2019, 21, 460-463.	0.5	1
218	Subsegmental pulmonary embolism: May not be a killer but indicates significant risk. <i>Thrombosis Research</i> , 2020, 185, 180-182.	0.8	1
219	Antibodies to the Platelet Factor 4-Heparin Complex and Mortality in Chronic Hemodialysis Patients.. <i>Blood</i> , 2006, 108, 274-274.	0.6	1
220	Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study. <i>Blood</i> , 2021, 138, 671-671.	0.6	1
221	Persistence of Platelets Activation Prior to Second Doses of Covid-19 Vaccine After Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210862.	0.7	1
222	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. <i>Annals of Internal Medicine</i> , 2022, 175, W43-W44.	2.0	1
223	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e35.	0.6	0
224	Unusual venous thrombosis. <i>Cmaj</i> , 2014, 186, 697.3-698.	0.9	0
225	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e13.	0.6	0
226	A Survey of the Use of Empiric Novel Anticoagulants During Investigation of Stroke. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 135-137.	0.3	0
227	Screening for cancer in unprovoked venous thromboembolism. <i>HemaSphere</i> , 2019, 3, 22-23.	1.2	0
228	Predictors of long-term cancer diagnosis after an unprovoked thromboembolic event: A post-hoc analysis of the REVERSE cohort study. <i>Thrombosis Research</i> , 2020, 185, 132-134.	0.8	0
229	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020, 196, 437-443.	0.8	0
230	Antithrombotic regimens in females with symptomatic lower extremity peripheral arterial disease: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e042980.	0.8	0
231	Media portrayals of pulmonary embolism. <i>Thrombosis Research</i> , 2021, 206, 52-54.	0.8	0
232	High Prevalence of Antibodies to the Heparin-Platelet Factor 4 Complex in Hemodialysis Patients.. <i>Blood</i> , 2005, 106, 4119-4119.	0.6	0
233	Practical Application of the 10 Mg Warfarin Initiation Nomogram. <i>Blood</i> , 2008, 112, 4054-4054.	0.6	0
234	Perioperative Management Of Patients On Dabigatran â€” a Prospective Cohort Study. <i>Blood</i> , 2013, 122, 3637-3637.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Risk of Venous Thromboembolism in Hospitalized Patients with Sickle Cell Disease. Blood, 2016, 128, 4755-4755.	0.6	0
236	Thrombotic and Bleeding Outcomes Following Perioperative Interruption of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation - a Comparative Analysis. Blood, 2018, 132, 1234-1234.	0.6	0
237	Long-Term Risk Factors for Occult Cancer Detection in Patients with Unprovoked Venous Thromboembolism: A Post-Hoc Analysis of the Reverse Study. Blood, 2018, 132, 1230-1230.	0.6	0
238	Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy. Blood, 2019, 134, 329-329.	0.6	0
239	Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis. Blood, 2019, 134, 4669-4669.	0.6	0
240	Expanding a First-Order Logic Mitigation Framework to Handle Multimorbid Patient Preferences. AMIA ... Annual Symposium proceedings, 2015, 2015, 895-904.	0.2	0
241	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 2139-2139.	0.6	0
242	A Population Cohort Study to Evaluate the Risk of Ischemic Stroke Among Individuals with a New Diagnosis of Cancer Compared to Matched Cancer-Free Controls: Impact of Prior Stroke History. Blood, 2021, 138, 175-175.	0.6	0
243	Efficacy and Safety of Apixaban for Primary Prevention of Thromboembolism in Cancer Patients with a Newly Inserted Central Venous Catheter: A Post-Hoc Analysis of the Avert Trial. Blood, 2021, 138, 2133-2133.	0.6	0
244	Impact of Race/Ethnicity on Cancer Associated Thrombosis Among Underserved Patients with Cancer. Blood, 2021, 138, 176-176.	0.6	0
245	A Framework for Modeling Workflow Execution by an Interdisciplinary Healthcare Team. Studies in Health Technology and Informatics, 2015, 216, 1100.	0.2	0
246	Rebuttal From Dr Tritschler et al. Chest, 2022, , .	0.4	0
247	Towards a framework for comparing functionalities of multimorbidity clinical decision support: A literature-based feature set and benchmark cases.. AMIA ... Annual Symposium proceedings, 2021, 2021, 920-929.	0.2	0
248	Step down to six months of prophylactic low-molecular-weight heparin after initial full-dose anticoagulation for the treatment of cancer-associated thrombosis (STEP-CAT): a pilot study. Journal of Thrombosis and Haemostasis, 2022, , .	1.9	0